Key takeaways
- A full-text search of the October 2026 Poisons Standard found no entry for MOTS-c (18 Nov 2026), and we found no TGA statement applying any of its group entries to MOTS-c.
- The Poisons Standard sets the level of control on a poison’s availability; whether therapeutic goods may be supplied at all is set by the Therapeutic Goods Act 1989.
- Under section 19B of the Act, importing, exporting, manufacturing or supplying therapeutic goods for use in humans that are not registered, listed, exempt or approved is an offence.
- The TGA says “research use only” disclaimers alone do not change a product’s regulatory status, permit importation or remove advertising or supply obligations.
- Sport Integrity Australia, which defines unapproved peptide products as goods not included in the ARTG, gives MOTS-C as an example of an unapproved peptide that is prohibited in sport; WADA names it in class S4.4.1.
01Is MOTS-c in the Poisons Standard?
Not by name. The instrument in force is the Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). It was made on 28 September, registered on 30 September and commenced on 1 October 2026.
Our search. On 18 November 2026 we searched the instrument’s full text, all 677 pages, for “MOTS”, “mitochondrial”, “12S”, the peptide’s amino-acid sequence, “AMPK” and “AICAR”. None appears. The Standard also has group entries, and we found no TGA statement applying any of them to MOTS-c; we draw no scheduling conclusion of our own.
What the Standard does. Its reader’s guide calls it “a compilation of decisions” on “the classification of poisons into Schedules, as recommendations to Australian States and Territories”, and says: “The scheduling classification sets the level of control on the availability of poisons.” The explanatory statement adds that the Schedules “are incorporated by reference in State and Territory legislation”, which is where supply and possession offences sit.
Scheduling is not approval. The Standard sets controls on availability. Whether a product may be imported, manufactured or supplied at all is a question for the Therapeutic Goods Act 1989, in the next section.
| Instrument | What it decides | MOTS-c, as of 18 Nov 2026 |
|---|---|---|
| Poisons Standard, October 2026 | Which Schedule a substance sits in, and the supply and possession controls that follow | Not named; no TGA statement applying a group entry found |
| Therapeutic Goods Act 1989 | Whether therapeutic goods may be imported, exported, manufactured or supplied for use in humans | Turns on how a product is presented and used; a peptide product not included in the ARTG is unapproved, the TGA says |
| WADA Prohibited List | Prohibited substances for athletes under the World Anti-Doping Code | Named in class S4.4.1, prohibited at all times |
02When is a MOTS-c product a therapeutic good?
It depends on how the product is presented and used. Australian law sorts products, not molecules.
The definition. Section 3 of the Therapeutic Goods Act 1989 defines therapeutic goods as goods “represented in any way to be, or that are, whether because of the way in which the goods are presented or for any other reason, likely to be taken to be” for therapeutic use. Therapeutic use includes “influencing, inhibiting or modifying a physiological process in persons”.
The TGA’s reading for peptides. Its peptide products page, last updated on 23 September 2026, says a peptide product is regulated as a therapeutic good if, for example, it is “promoted, supplied or generally used for a therapeutic purpose”. It adds: “While some peptide products are approved for use in Australia, many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise.” The TGA’s April 2026 advisory states that “peptide products are regulated as therapeutic goods in Australia” and that “Unapproved peptide products are goods which have not been included in the ARTG”, the Australian Register of Therapeutic Goods.
The core offence. Section 19B makes it an offence to import, export, manufacture or supply in Australia therapeutic goods for use in humans unless they are registered or listed, exempt, or approved under sections 19 or 19A. The maximum is 12 months’ imprisonment, 1,000 penalty units or both. It rises to 5 years, 4,000 penalty units or both where use of the goods has caused, or is likely to cause, harm or injury.
Labels. The April 2026 advisory says: “Disclaimers that a product is for ‘research use only’ does not make its supply lawful.” Such disclaimers alone do not “change a product’s regulatory status”, “permit importation” or “remove advertising or supply obligations”. More: what “research use only” means.
| Provision or statement | What it says | Source |
|---|---|---|
| Act, s 3 | Therapeutic goods are judged by how they are represented or presented, and by their likely use | Therapeutic Goods Act 1989 |
| Act, s 19B(4) | Importing, exporting, manufacturing or supplying unapproved therapeutic goods for use in humans: up to 12 months, 1,000 penalty units or both | Therapeutic Goods Act 1989 |
| Act, s 19B(1) | The same, where use has caused or is likely to cause harm or injury: up to 5 years, 4,000 penalty units or both | Therapeutic Goods Act 1989 |
| Research labels | Disclaimers alone do not change regulatory status, permit importation or remove advertising or supply obligations | TGA, 13 Apr 2026 |
| Manufacture | Includes “applying a label to a blank vial, packaging for distribution, and storage of the products before they are in their final state” | TGA, 20 Jul 2026 |
03What has the TGA done about peptide products in 2026?
The TGA’s 2026 statements address unapproved peptide products as a group. Dates and wording come from the TGA documents.
| Date | What the TGA did or said |
|---|---|
| 13 Apr 2026 | Safety advisory: peptide products are regulated as therapeutic goods, and “research use only” disclaimers do not make supply lawful. |
| 7 May 2026 | Warns that peptide imports that do not meet importation requirements because of poor or unclear labelling will be referred to the Australian Border Force “to seize and destroy”. |
| 10 Jun 2026 | Expands its priority focus areas to include unapproved peptide products, “following increased detection of unlawful importation, supply and advertising”. |
| 20 Jul 2026 | Puts promoters and suppliers of unapproved peptide products on notice, and says labelling a blank vial counts as manufacture. |
| 17 Aug 2026 | States: “It is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia.” |
| 23 Sep 2026 | Updates its peptide products page, which explains when a peptide product is regulated as a therapeutic good. |
| 1 Oct 2026 | The October 2026 Poisons Standard commences. It has no entry for MOTS-c. |
The law that would decide a MOTS-c product’s status did not change in 2026. What changed is how actively the TGA polices peptide products. Its releases describe seizures, notices and tests by product type, not compound by compound. For the rules that apply to every peptide, see are peptides legal in Australia?
04How is MOTS-c treated in Australian sport?
WADA’s Prohibited List names MOTS-c in class S4.4.1, metabolic modulators, among activators of the AMP-activated protein kinase (AMPK). The class is prohibited in and out of competition, and the List says substances in S4.4 are non-Specified Substances.
Sport Integrity Australia’s peptides page says “Many unapproved peptides are prohibited in sport” and gives MOTS-C among its “common examples”. It defines unapproved peptide products as goods not included in the ARTG. It says possession or use of prohibited peptide products by athletes can lead to an anti-doping rule violation and a ban from sport, and that “A TUE is unlikely to be granted for an unregistered medicine”, a TUE being a therapeutic use exemption. Detail: is MOTS-c banned in sport?
05What we don’t know
The ARTG itself. We could not search the ARTG, because tga.gov.au did not respond to our tools on 18 November 2026. The TGA pages cited here were read on the Internet Archive.
Scheduling proposals. We did not search the TGA’s scheduling consultations for MOTS-c, so we cannot say whether a delegate has considered it.
State and territory detail. Poisons and therapeutic goods laws differ by jurisdiction, and we have not summarised them.
Compound-level enforcement. The TGA’s releases do not report actions compound by compound.
For the UK and US positions, see is MOTS-c legal in the UK? and is MOTS-c legal in the US? The evidence on MOTS-c itself is in our MOTS-c research guide. Changes are logged in our regulatory changelog.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.